US Diabetes Drug Market, Dosage, Price, Sales Insight 2021 - 2026

Table of Contents

1. US Diabetes Drugs Market - Prevalence & Statistics

2. US Diabetes Drugs Market Overview
2.1 Current Market Scenario
2.2 Clinical Trials Landscape

3. US Insulins Based Drugs - Branded & Generic Availability, Dosage, Patent, Price & Sales Analysis
3.1 Insulin Lispro
3.2 Insulin Glargine
3.3 Insulin Aspart
3.4 Insulin Detemir
3.5 Insulin Regular
3.6 Insulin Aspart / Insulin Aspart Protamine
3.7 Insulin Degludec
3.8 Insulin Glulisine
3.9 Insulin Inhalation
3.10 Insulin Isophane / Insulin Regular
3.11 Insulin Isophane
3.12 Insulin Lispro / Insulin Lispro Protamine

4. Non-Sulfonylureas - Branded & Generic Availability, Dosage, Patent, Price & Sales Analysis
4.1 Metformin

5. Sulfonylureas - Branded & Generic Availability, Dosage, Patent, Price & Sales Analysis
5.1 Chlorpropamide
5.2 Glimepiride
5.3 Glyburide
5.4 Glipizide
5.5 Tolazamide
5.6 Tolbutamide

6. Thiazolidinediones - Branded & Generic Availability, Dosage, Patent & Price Analysis
6.1 Pioglitazone
6.2 Rosiglitazone

7. Incretin mimetics - Branded & Generic Availability, Dosage, Patent, Price & Sales Analysis
7.1 Liraglutide
7.2 Exenatide
7.3 Semaglutide
7.4 Dulaglutide
7.5 Lixisenatide

8. Dipeptidyl peptidase 4 inhibitors - Branded & Generic Availability, Dosage, Patent, Price & Sales Analysis
8.1 Sitagliptin
8.2 Saxagliptin
8.3 Linagliptin
8.4 Alogliptin

9. SGLT-2 inhibitors - Branded & Generic Availability, Dosage, Patent, Price & Sales Analysis
9.1 Canagliflozin
9.2 Ertugliflozin
9.3 Empagliflozin
9.4 Dapagliflozin

10. Meglitinides - Branded & Generic Availability, Dosage, Patent & Price Analysis
10.1 Repaglinide
10.2 Nateglinide

11. Alpha-glucosidase inhibitors - Branded & Generic Availability, Dosage, Patent & Price Analysis
11.1 Miglitol
11.2 Acarbose

12. Combinational - Branded & Generic Availability, Dosage, Patent, Price & Sales Analysis
12.1 Metformin/Sitagliptin
12.2 Glimepiride/Pioglitazone
12.3 Glyburide/Metformin
12.4 Dapagliflozin/Metformin
12.5 Empagliflozin/Metformin
12.6 Glipizide/Metformin
12.7 Linagliptin/Metformin
12.8 Metformin/Pioglitazone
12.9 Metformin / Saxagliptin (Kombiglyze XR)
12.10 Alogliptin / Metformin (Kazano)
12.11 Alogliptin / Pioglitazone (Oseni)
12.12 Canagliflozin/Metformin (Invokamet/ Invokamet XR)
12.13 Dapagliflozin / Saxagliptin (Qtern)
12.14 Empagliflozin / Linagliptin / Metformin
12.15 Empagliflozin / Linagliptin (Glyxambi)
12.16 Ertugliflozin / Metformin (Segluromet)
12.17 Ertugliflozin / Sitagliptin (Steglujan)

13. Other Antidiabetic Drugs - Branded & Generic Availability, Dosage, Patent & Price Analysis
13.1 Bromocriptine (Cycloset)
13.2 Colesevelam (Welchol)
13.3 Pramlintide (Symlin)

14. Compititive Landscape
14.1 AstraZeneca
14.2 Boehringer Ingelheim
14.3 Daiichi Sankyo
14.4 Eli Lilly
14.5 GSK
14.6 Janssen Pharma
14.7 Merck
14.8 Novartis
14.9 Novo Nordisk
14.10 Pfizer
14.11 Sanofi
14.12 Takeda

List of Figures

Figure 1-1: US - Estimated Diabetic Population (Million), 2019, 2025, 2030 & 2045
Figure 1-2: US - Undiagnosed & Diagnosed Diabetic Population (Million), 2019
Figure 1-3: US - Undiagnosed & Diagnosed Diabetic Population (%), 2019
Figure 1-4: US - Estimated Diabetic Prevalence Rate (%), 2019, 2025, 2030 & 2045
Figure 1-5: US - Diabetic Population by Type (Million), 2019
Figure 1-6: US - Diabetic Population by Type (%), 2019
Figure 1-7: US - Type 1 Diabetes Cases by Age (Million), 2019
Figure 1-8: US - Maximum Diabetic Prevalence Rate by States (%), 2020
Figure 1-9: US - Minimum Diabetic Prevalence Rate by States (%), 2020
Figure 2-1: US - Diabetes Drug Market Opportunity (US$ Billion), 2019 - 2026
Figure 2-2: Global - Diabetes Drug Market Opportunity (US$ Billion), 2019 - 2026
Figure 2-3: North America - Diabetes Drug Market Size US v/s Others (US$ Billion), 2020
Figure 2-4: US - Insulin Market Opportunity (US$ Billion), 2019 - 2026
Figure 2-5: US - Diabetes Drug Market by Product (US Billion), 2020
Figure 2-6: US - Diabetes Drug Market by Product (%), 2020
Figure 2-7: US - Number of Diabetes Drug Clinical Pipeline by Phase, 2021 - 2026
Figure 2-8: US - Number of Diabetes Drugs in Clinical Pipeline by Drug Class, 2021 - 2026
Figure 2-9: US - Number of Diabetes Drugs in Clinical Pipeline by Organization, 2021 - 2026
Figure 2-10: US - Number of Diabetes Drugs in Clinical Pipeline by Patient Segment, 2021 - 2026
Figure 3-1: US - Insulin Lispro FDA Approval & Patent Expiration Year
Figure 3-2: US - FDA Approval History by Brand Name
Figure 3-3: Humalog - Cost of Supply of 3ml & Per Unit Price of Injectable Solution (US$), February’2021
Figure 3-4: Humalog - Cost of Supply of 10ml & Per Unit Price of Injectable Solution (US$), February’2021
Figure 3-5: Humalog KwikPen - Cost of 15ml & Per Unit Cost of Injectable Solution (US$), February’2021
Figure 3-6: Humalog KwikPen - Cost of 6ml & Per Unit Cost of Subcutaneous Solution (US$), February’2021
Figure 3-7: Admelog - Cost of Supply of 3ml & Per Unit Price of Injectable Solution (US$), February’2021
Figure 3-8: Admelog - Cost of Supply of 10ml & Per Unit Price of Injectable Solution (US$), February’2021
Figure 3-9: Lyumjev - Cost of Supply of 10ml & Per Unit Price of Injectable Solution (US$), February’2021
Figure 3-10: Humalog Junior KwikPen - Cost of Supply of 15ml & Per Unit Price of Injectable Solution (US$), February’2021
Figure 3-11: Insulin Lipro - Cost of Supply of 10ml & Per Unit Price of Injectable Solution (US$), February’2021
Figure 3-12: Insulin Lispro - Price Per ml By Brand Name (US$)
Figure 3-13: Global - Humalog Annual Sales (US$ Million), 2017-2020
Figure 3-14: Global - Admelog Annual Sales (US$ Million), 2018 & 2019
Figure 3-15: US - Admelog Annual Sales (US$ Million), 2018 & 2019
Figure 3-16: Admelog - Annual Sales by Region (US$ Million), 2019
Figure 3-17: Admelog - Annual Sales by Region (%), 2019
Figure 3-18: Global - Admelog Quarterly Sales (US$ Million), 2019
Figure 3-19: US - Admelog Quarterly Sales (US$ Million), 2019
Figure 3-20: Global - Admelog Quarterly Sales (US$ Million), 2020
Figure 3-21: US - Insulin Glagrine FDA Approval & Patent Expiration Year
Figure 3-22: Insulin Glagrine - FDA Approval History by Brand
Figure 3-23: Lantus - Cost of Supply of 10ml & Per Unit Price of Subcutaneous Solution (US$), February’2021
Figure 3-24: Basaglar - Cost of Supply of 15ml & Per Unit Price of Subcutaneous Solution (US$), February’2021
Figure 3-25: Toujeo - Cost of Supply of 4.5ml & Per Unit Price of Subcutaneous Solution (US$), February’2021
Figure 3-26: Lantus Solostar- Cost of Supply of 15ml & Per Unit Price of Subcutaneous Solution (US$), February’2021
Figure 3-27: Semglee - ost of Supply of 10ml & Per Unit Price of Subcutaneous Solution (US$), February’2021
Figure 3-28: Global - Lantus Annual Sales (US$ Million), 2017-2019
Figure 3-29: US - Lantus Annual Sales (US$ Million), 2017- 2019
Figure 3-30: Lantus - Annual Sales by Region (US$ Million), 2019
Figure 3-31: Lantus - Annual Sales by Region (%), 2019
Figure 3-32: Global - Lantus Quarterly Sales (US$ Million), 2019
Figure 3-33: US -Lantus Quarterly Sales (US$ Million), 2019
Figure 3-34: Global - Lantus Quarterly Sales (US$ Million), 2020
Figure 3-35: US - Lantus Quarterly Sales (US$ Million), 2020
Figure 3-36: Lantus - Annual Sales by Region (%), 2020
Figure 3-37: Global -Basaglar Annual Sales (US$ Million), 2017-2020
Figure 3-38: Global - Toujeo Annual Sales (US$ Million), 2017-2019
Figure 3-39: US - Toujeo Annual Sales (US$ Million), 2017- 2019
Figure 3-40: Toujeo - Annual Sales by Region (US$ Million), 2019
Figure 3-41: Toujeo - Annual Sales by Region (%), 2019
Figure 3-42: Global - Toujeo Quarterly Sales (US$ Million), 2019
Figure 3-43: US - Toujeo Quarterly Sales (US$ Million), 2019
Figure 3-44: Global - Toujeo Quarterly Sales (US$ Million), 2020
Figure 3-45: US - Toujeo Quarterly Sales (US$ Million), 2020
Figure 3-46: Toujeo - Annual Sales by Region (%), 2020
Figure 3-47: US - Insulin Aspart FDA Approval & Patent Expiration Year
Figure 3-48: US - FDA Approval History by Brand
Figure 3-49: Novolog - Cost of Supply of 10ml & Per Unit Price of Injectable Solution (US$), Fbruary’2021
Figure 3-50: Novolog PenFill - Cost of Supply of 15ml & Per Unit Price of Injectable Solution (US$), February’2021
Figure 3-51: Fiasp - Cost of Supply of 15ml & Per Unit Price of Injectable Solution (US$), February’2021
Figure 3-52: Fiasp - Cost of Supply of 10ml & Per Unit Price of Injectable Solution (US$), February’2021
Figure 3-53: Insulin Aspart - Cost of Supply of 10ml & Per Unit Price of Injectable Solution (US$), February’2021
Figure 3-54: Global - Fiasp Annual Sales (US$ Million), 2018-2020
Figure 3-55: US - Fiasp Annual Sales (US$ Million), 2018-2020
Figure 3-56: Fiasp - Annual Sales by Region (%), 2019
Figure 3-57: Fiasp - Annual Sales by Region (%), 2020
Figure 3-58: US - Insulin Detemir FDA Approval & Patent Expiration Year
Figure 3-59: Levemir - Cost of Supply of 10ml & Per Unit Price of Injectable Solution (US$), February’2021
Figure 3-60: Global - Levemir Annual Sales (US$ Million), 2018-2020
Figure 3-61: US - Levemir Annual Sales (US$ Million), 2018-2020
Figure 3-62: Levemir - Annual Sales by Region (%), 2019
Figure 3-63: Levemir - Annual Sales by Region (%), 2020
Figure 3-64: US - Insulin Regular FDA Approval & Patent Expiration Year
Figure 3-65: Insulin Regular - FDA Approval Year by Brand
Figure 3-66: Humulin - Cost of Supply of 3ml & Per Unit Price of Injectable Solution (US$), February’2021
Figure 3-67: Humulin - Cost of Supply of 10ml & Per Unit Price of Injectable Solution (US$), February’2021
Figure 3-68: Novolin - Cost of Supply of 10ml & Per Unit Price of Injectable Solution (US$), February’2021
Figure 3-69: Humulin R U-500 - Cost of Supply of 20ml & Per Unit Price of Injectable Solution (US$), February’2021
Figure 3-70: Humulin KwikPen- Cost of Supply of 6ml & Per Unit Price of Subcutaneous Solution (US$), February’2021
Figure 3-71: Myxredlin- Cost of Supply of 1200ml & Per Unit Price of Intravenous Solution (US$), February’2021
Figure 3-72: Global - Humulin Annual Sales (US$ Million), 2017-2020
Figure 3-73: Novolog Mix 70/30 - Cost of Supply of 10ml & Per Unit Price of Subcutaneous Solution (US$), February’2021
Figure 3-74: Novolog Mix 70/30 FlexPen - Cost of Supply of 15ml & Per Unit Price of Subcutaneous Solution (US$), February’2021
Figure 3-75: Insulin Aspart/Insulin Aspart Protamine - Cost of Supply of 15ml & Per Unit Price of Subcutaneous Solution (US$), February’2021
Figure 3-76: Insulin Aspart/Insulin Aspart Protamine - Cost of Supply of 10ml & Per Unit Price of Subcutaneous Solution (US$), February’2021
Figure 3-77: Global - NovoMix Annual Sales (US$ Million), 2018-2020
Figure 3-78: US - NovoMix Annual Sales (US$ Million), 2018-2020
Figure 3-79: NovoMix - Annual Sales by Region (%), 2019
Figure 3-80: NovoMix - Annual Sales by Region (%), 2020
Figure 3-81: US - Insulin Degludec FDA Approval & Patent Expiration Year
Figure 3-82: Tresiba- Cost of Supply of 10ml & Per Unit Price of 100units/ml Subcutaneous Solution (US$), February’2021
Figure 3-83: Tresiba- Cost of Supply of 15ml & Per Unit Price of 100units/ml Subcutaneous Solution (US$), February’2021
Figure 3-84: Tresiba- Cost of Supply of 9ml & Per Unit Price of 200units/ml Subcutaneous Solution (US$), February’2021
Figure 3-85: Global - Tresiba Annual Sales (US$ Million), 2018-2020
Figure 3-86: US - Tresiba Annual Sales (US$ Million), 2018-2020
Figure 3-87: Tresiba - Annual Sales by Region (%), 2019
Figure 3-88: Tresiba - Annual Sales by Region (%), 2020
Figure 3-89: US - Insulin Glusine FDA Approval & Patent Expiration Year
Figure 3-90: US - FDA Approval Year by Brand
Figure 3-91: Apidra - Cost of Supply of 10ml & Per Unit Price of injectable solution (US$), February’2021
Figure 3-92: Global - Apidra Annual Sales (US$ Million), 2017-2019
Figure 3-93: US - Apidra Annual Sales (US$ Million), 2017- 2019
Figure 3-94: Apidra - Annual Sales by Region (US$ Million), 2019
Figure 3-95: Apidra - Annual Sales by Region (%), 2019
Figure 3-96: Global - Apidra Quarterly Sales (US$ Million), 2019
Figure 3-97: US - Apidra Quarterly Sales (US$ Million), 2019
Figure 3-98: Global - Apidra Quarterly Sales (US$ Million), 2020
Figure 3-99: US - Apidra Quarterly Sales (US$ Million), 2020
Figure 3-100: Apidra - Annual Sales by Region (%), 2020
Figure 3-101: Afrezza - Cost of Supply of 90 Powders & Per Unit Cost of 4 Units Powder (US$), February’2021
Figure 3-102: Afrezza - Cost of Supply of 90 Powders & Per Unit Cost of 8 Units Powder (US$), February’2021
Figure 3-103: Afrezza - Cost of Supply of 90 Powders & Per Unit Cost of 12 Units Powder (US$), February’2021
Figure 3-104: Insulin Isophane/Insulin Regular - FDA Approval Year by Brand
Figure 3-105: Humulin 70/30 - Cost of Supply of 10ml & Per Unit Price of Subcutaneous Suspension (US$), February’2021
Figure 3-106: Humulin 70/30 - Cost of Supply of 3ml & Per Unit Price of Subcutaneous Suspension (US$), February’2021
Figure 3-107: Humulin 70/30 Pen - Cost of Supply of 15ml & Per Unit Price of Subcutaneous Suspension (US$), February’2021
Figure 3-108: Novolin 70/30 - Cost of Supply of 10ml & Per Unit Price of Subcutaneous Suspension (US$), February’2021
Figure 3-109: ReliON - Cost of Supply of 10ml & Per Unit Price of Subcutaneous Suspension (US$), February’2021
Figure 3-110: Insulin Isophane - FDA Approval Year by Brand
Figure 3-111: Humulin N - Cost of Supply of 3ml & Per Unit Price of Subcutaneous Suspension (US$), February’2021
Figure 3-112: Humulin N - Cost of Supply of 10ml & Per Unit Price of Subcutaneous Suspension (US$), February’2021
Figure 3-113: Humulin N Pen - Cost of Supply of 15ml & Per Unit Price of Injectable Solution (US$), February’2021
Figure 3-114: Novolin N - Cost of Supply of 10ml & Per Unit Price of Injectable Solution (US$), February’2021
Figure 3-115: Humalog Mix 50/50 - Cost of Supply of 10ml & Per Unit Price of Subcutaneous Suspension (US$), February’2021
Figure 3-116: Humalog Mix 50/50 Pen - Cost of Supply of 15ml & Per Unit Price of Subcutaneous Suspension (US$), February’2021
Figure 3-117: Humalog Mix 75/25 - Cost of Supply of 10ml & Per Unit Price of Subcutaneous Suspension (US$), February’2021
Figure 3-118: Humalog Mix 50/50 Pen - Cost of Supply of 15ml & Per Unit Price of Subcutaneous Suspension (US$), February’2021
Figure 4-1: Metformin - FDA Approval & 1st Generic Approval Year
Figure 4-2: Metformin - FDA Approval Year by Brand
Figure 4-3: US - Glumetza Patent Approval & Expiration Year
Figure 4-4: US - Riomet Patent Approval & Expiration Year
Figure 4-5: Glumetza - Cost of Supply of 100 Tablets & Per Unit Price of 500mg Oral Tablet (US$), February’2021
Figure 4-6: Glumetza - Cost of Supply of 90 Tablets & Per Unit Price of 1000mg Oral Tablet (US$), February’2021
Figure 4-7: Glumetza - Per Unit Cost of 500mg & 100mg Oral Tablet (US$), February’2021
Figure 4-8: Glumetza - Maximum & Minimum Recommended Dose (mg)
Figure 4-9: Riomet - Cost of Supply of 118ml & Per Unit Price of Oral Soltuion (US$), February’2021
Figure 4-10: Riomet - Cost of Supply of 473ml & Per Unit Price of Oral Soltuion (US$), February’2021
Figure 4-11: Riomet - Maximum & Minimum Recommended Dose (mg)
Figure 4-12: Riomet - Cost of Supply of 118ml & 473ml of Oral Soltuion (US$), February’2021
Figure 4-13: Metformin - Cost of Supply of 30, 90 & 100 Oral Tablets (500mg) (US$), February’2021
Figure 4-14: Metformin - Cost of Supply of 30, 90 & 100 Oral Tablets (850mg) (US$), February’2021
Figure 4-15: Metformin - Cost of Supply of 30, 90 & 100 Oral Tablets (1000mg) (US$), February’2021
Figure 4-16: Metformin - Cost of Supply of 30, 90 & 100 Oral ER Tablets (750mg) (US$), February’2021
Figure 5-1: Chlorpropamide - Cost of Supply of 30 & 60 Oral Tablets (250mg) (US$), February’2021
Figure 5-2: Chlorpropamide - Cost of Supply of 30 & Per Unit Price of Oral Tablets (100mg) (US$), February’2021
Figure 5-3: Chlorpropamide - Maximum & Minimum Recommended Dose (mg)
Figure 5-4: Glimepiride - FDA Approval & 1st Generic Approval Year
Figure 5-5: US - Glimepiride Patent Approval & Expiration Year
Figure 5-6: Amaryl - Cost of Supply of 100 Tablets & Per Unit Price of 1mg Oral Tablet (US$), February’2021
Figure 5-7: Amaryl - Cost of Supply of 100 Tablets & Per Unit Price of 2mg Oral Tablet (US$), February’2021
Figure 5-8: Amaryl - Cost of Supply of 100 Tablets & Per Unit Price of 4mg Oral Tablet (US$), February’2021
Figure 5-9: Glimepiride - Cost of Supply of 30, 90 & 100 Oral Tablets (1mg) (US$), February’2021
Figure 5-10: Glimepiride - Cost of Supply of 30, 90 & 100 Oral Tablets (2mg) (US$), February’2021
Figure 5-11: Glimepiride - Cost of Supply of 30, 90 & 100 Oral Tablets (4mg) (US$), February’2021
Figure 5-12: Glimepiride - Maximum & Minimum Recommended Dose (mg)
Figure 5-13: Glyburide - FDA Approval & 1st Generic Approval Year
Figure 5-14: DiaBeta - Cost of Supply of 50 Tablets & Per Unit Price of 1.25mg Oral Tablet (US$), February’2021
Figure 5-15: DiaBeta - Cost of Supply of 100 Tablets & Per Unit Price of 2.25mg Oral Tablet (US$), February’2021
Figure 5-16: DiaBeta - Cost of Supply of 100 Tablets & Per Unit Price of 5mg Oral Tablet (US$), February’2021
Figure 5-17: Glynase PresTab - Cost of Supply of 100 Tablets & Per Unit Price of 1.5mg Oral Tablet (US$), February’2021
Figure 5-18: Glynase PresTab - Cost of Supply of 100 & 1000 Tablets of 3mg Oral Tablet (US$), February’2021
Figure 5-19: Glynase PresTab - Cost of Supply of 100 & 500 Tablets of 6mg Oral Tablet (US$), February’2021
Figure 5-20: Glyburide- Cost of Supply of 50 & 100 Tablets of 1.5mg Oral Tablet (US$), February’2021
Figure 5-21: Glyburide- Cost of Supply of 30, 90 & 100 Tablets of 2.5mg Oral Tablet (US$), February’2021
Figure 5-22: Glyburide- Cost of Supply of 30, 90 & 100 Tablets of 5mg Oral Tablet (US$), February’2021
Figure 5-23: Glyburide - Cost of Supply of 100 Tablets & Per Unit Price of 1.5mg Micronized Oral Tablet (US$), February’2021
Figure 5-24: Glyburide - Cost of Supply of 100 & 1000 Tablets of 3mg Micronized Oral Tablet (US$), February’2021
Figure 5-25: Glyburide - Cost of Supply of 100 & 1000 Tablets of 3mg Micronized Oral Tablet (US$), February’2021
Figure 5-26: Glyburide - Maximum & Minimum Recommended Dose of Standard Tablet (mg)
Figure 5-27: Glyburide - Maximum & Minimum Recommended Dose of Micronized Tablet (mg)
Figure 5-28: Glipizide - FDA Approval & 1st Generic Approval Year
Figure 5-29: Glucotrol - Cost of Supply of 100 Tablets & Per Unit Price of 5mg Oral Tablet (US$), February’2021
Figure 5-30: Glucotrol - Cost of Supply of 100 Tablets & Per Unit Price of 10mg Oral Tablet (US$), February’2021
Figure 5-31: Glucotrol XL - Cost of Supply of 30 Tablets & Per Unit Price of 2.5mg Oral Tablet (US$), February’2021
Figure 5-32: Glucotrol XL - Cost of Supply of 100 & 500 Tablets of 5mg Oral Tablet (US$), February’2021
Figure 5-33: Glucotrol XL - Cost of Supply of 100 & 500 Tablets of 10mg Oral Tablet (US$), February’2021
Figure 5-34: Glipizide - Cost of Supply of 30, 90 & 100 Oral Tablets (5mg) (US$), February’2021
Figure 5-35: Glipizide - Cost of Supply of 30, 90 & 100 Oral Tablets (10mg) (US$), February’2021
Figure 5-36: Glipizide - Cost of Supply of 30 Tablets & Per Unit Price of 2.5mg Oral ER Tablet (US$), February’2021
Figure 5-37: Glipizide - Cost of Supply of 100, 500 & 1000 of 5mg Oral ER Tablet (US$), February’2021
Figure 5-38: Glipizide - Cost of Supply of 100, 500 & 1000 of 10mg Oral ER Tablet (US$), February’2021
Figure 5-39: Glipizide - Maximum Recommended Dose by Oral Tablet (mg/day)
Figure 5-40: Tolzamide - Cost of Supply of 90 Tablets & Per Unit Cost of 250mg Tablet (US$), February’2021
Figure 5-41: Tolzamide - Cost of Supply of 100 Tablets & Per Unit Cost of 250mg Tablet (US$), February’2021
Figure 5-42: Tolzamide - Cost of Supply of 100 Tablets & Per Unit Cost of 500mg Tablet (US$), February’2021
Figure 5-43: Tolzamide - Maximum & Minimum Recommended Dose (mg)
Figure 5-44: Tolbutamide - Cost of Supply of 100 Tablets & Per Unit Cost of 500mg Tablet (US$), February’2021
Figure 5-45: Tolbutamide - Maximum & Minimum Recommended Dose (mg)
Figure 6-1: Pioglitazone - FDA Approval & Patent Expiration Year
Figure 6-2: Pioglitazone - FDA Approval & 1st Generic Approval Year
Figure 6-3: Actos - Cost of Supply of 30, 90 & 500 Tablets of 15mg Oral Tablet (US$), February’2021
Figure 6-4: Actos - Cost of Supply of 30 & 500 Tablets of 30mg Oral Tablet (US$), February’2021
Figure 6-5: Actos - Cost of Supply of 30 & 500 Tablets of 45mg Oral Tablet (US$), February’2021
Figure 6-6: Pioglitazone - Cost of Supply of 30, 90 & 500 Tablets of 15mg Oral Tablet (US$), February’2021
Figure 6-7: Pioglitazone - Cost of Supply of 30, 90 & 500 Tablets of 30mg Oral Tablet (US$), February’2021
Figure 6-8: Pioglitazone - Cost of Supply of 30, 90 & 500 Tablets of 45mg Oral Tablet (US$), February’2021
Figure 6-9: Pioglitazone - Maximum & Minimum Recommended Dose (mg)
Figure 6-10: Pioglitazone - Maximum & Minimum Cost of Treatment per Day with Branded & Generic Drugs
Figure 6-11: US - Rosiglitazone Patent Approval & Expiration Year
Figure 6-12: Rosiglitazone - Cost of Supply of 60 Tablets & Per Unit Cost of 2mg Oral Tablet (US$), February’2021
Figure 6-13: Rosiglitazone - Cost of Supply of 30 Tablets & Per Unit Cost of 4mg Oral Tablet (US$), February’2021
Figure 6-14: Rosiglitazone - Maximum & Minimum Recommended Dose (mg)
Figure 7-1: Liraglutide - FDA Approval & Patent Expiration Year
Figure 7-2: Victoza - Cost of Supply of 6ml & Per Unit Cost of Subcutaneous Soltuion (US$), February’2021
Figure 7-3: Victoza - Cost of Supply of 9ml & Per Unit Cost of Subcutaneous Soltuion (US$), February’2021
Figure 7-4: Victoza - Maximum & Minimum Recommended Dose (mg)
Figure 7-5: Global - Victoza Annual Sales (US$ Million), 2018-2020
Figure 7-6: US - Victoza Annual Sales (US$ Million), 2018-2020
Figure 7-7: Victoza - Annual Sales by Region (%), 2019
Figure 7-8: Victoza - Annual Sales by Region (%), 2020
Figure 7-9: US - Exenatide FDA Approval & Patent Expiration Year
Figure 7-10: US - Exenatide FDA Approval by Brand
Figure 7-11: Byetta - Cost of Supply of 1.2ml & Per Unit Cost of 5mcg/0.02ml Subcutaneous Soltuion (US$), February’2021
Figure 7-12: Byetta - Cost of Supply of 2.4ml & Per Unit Cost of 10mcg/0.04ml Subcutaneous Soltuion (US$), February’2021
Figure 7-13: Bydureon - Cost of Supply of 4 & Per Unit Cost of 2mg Subcutaneous Powder (US$), February’2021
Figure 7-14: Bydureon BCise - Cost of Supply of 3.4ml & Per Unit Cost of Subcutaneous Suspension (US$), February’2021
Figure 7-15: Global - Bydureon Annual Sales (US$ Million), 2017-2019
Figure 7-16: US - Bydureon Annual Sales (US$ Million), 2017-2019
Figure 7-17: Bydureon - Annual Sales by Region (%), 2019
Figure 7-18: Global - Bydureon Quarterly Sales (US$ Million), 2020
Figure 7-19: US - Bydureon Quarterly Sales (US$ Million), 2020
Figure 7-20: Bydureon - Annual Sales by Region (%), 2020
Figure 7-21: Global - Byetta Annual Sales (US$ Million), 2017-2019
Figure 7-22: US - Byetta Annual Sales (US$ Million), 2017-2019
Figure 7-23: Byetta - Annual Sales by Region (%), 2019
Figure 7-24: Global - Byetta Quarterly Sales (US$ Million), 2020
Figure 7-25: US - Byetta Quarterly Sales (US$ Million), 2020
Figure 7-26: Byetta - Annual Sales by Region (%), 2020
Figure 7-27: Semaglutide - FDA Approval & Patent Expiration Year
Figure 7-28: Semaglutide - FDA Approval by Brand
Figure 7-29: Ozempic - Cost of Supply of 1.5ml & Per Unit Price of Subcutaneous Solution (US$), February’2021
Figure 7-30: Ozempic - Cost of Supply of 3ml & Per Unit Price of Subcutaneous Solution (US$), February’2021
Figure 7-31: Ozempic - Maximum & Minimum Recommended Dose (mg)
Figure 7-32: Rybelsus - Cost of Supply of 30 Tablets & Per Unit Price of Oral Tablet (US$), February’2021
Figure 7-33: Rybelsus - Maximum & Minimum Recommended Dose (mg)
Figure 7-34: Global - Ozempic Annual Sales (US$ Million), 2018-2020
Figure 7-35: US - Ozempic Annual Sales (US$ Million), 2018-2020
Figure 7-36: Ozempic - Annual Sales by Region (%), 2019
Figure 7-37: Ozempic - Annual Sales by Region (%), 2020
Figure 7-38: Global - Rybelsus Annual Sales (US$ Million), 2019 & 2020
Figure 7-39: US - Rybelsus Annual Sales (US$ Million), 2019 & 2020
Figure 7-40: Rybelsus - Annual Sales by Region (%), 2020
Figure 7-41: US - Dulaglutide FDA Approval & Patent Exclusivity Year
Figure 7-42: Trulicity - Cost of Supply of 2ml & Per Unit Price of Subcutaneous Solution (US$), February’2021
Figure 7-43: Trulicity - Maximum & Minimum Recommended Dose (mg)
Figure 7-44: Global - Trulicity Annual Sales (US$ Million), 2017-2020
Figure 7-45: US - Lixisenatide FDA Approval & Patent Expiration Year
Figure 7-46: Adlyxin - Cost of Supply 6ml & Per Unit Price of Subcutaneous Kit/Solution (US$), February’2021
Figure 7-47: Adlyxin - Recommended Initial Dose & Maintenance Dose (mcg)
Figure 8-1: US - Sitagliptin FDA Approval & Patent Exclusivity Year
Figure 8-2: Januvia - Cost of Supply of 30, 90 & 100 Oral Tablets (US$), February’2021
Figure 8-3: Januvia -Recommended Initial Dose & Subsequent Reductions (mg)
Figure 8-4: Global - Januvia Annual Sales (US$ Million), 2017-2019
Figure 8-5: US - Januvia Annual Sales (US$ Million), 2017-2019
Figure 8-6: Januvia - Annual Sales by Region (%), 2019
Figure 8-7: Global - Januvia Quarterely Sales (US$ Million), 2020
Figure 8-8: US - Saxagliptin FDA Approval & Patent Expiration Year
Figure 8-9: Onglyza - Cost of Supply of 30 & Per Unit Price of Oral Tablet (US$), February’2021
Figure 8-10: Onglyza - Cost of Supply of 90 & Per Unit Price of Oral Tablet (US$), February’2021
Figure 8-11: Onglyza - Cost of Daily, Monthly & Annual Treatment (US$)
Figure 8-12: Global - Onglyza Annual Sales (US$ Million), 2017-2019
Figure 8-13: US - Onglyza Annual Sales (US$ Million), 2017-2019
Figure 8-14: Onglyza - Annual Sales by Region (%), 2019
Figure 8-15: Global - Onglyza Quarterly Sales (US$ Million), 2020
Figure 8-16: US - Onglyza Quarterly Sales (US$ Million), 2020
Figure 8-17: Onglyza - Annual Sales by Region (%), 2020
Figure 8-18: US - Linagliptin FDA Approval & Patent Expiration Year
Figure 8-19: Tradjenta - Cost of Supply of 30 & Per Unit Price of Oral Tablet (US$), February’2021
Figure 8-20: Tradjenta - Cost of Supply of 90 & Per Unit Price of Oral Tablet (US$), February’2021
Figure 8-21: Tradjenta - Cost of Supply of 100 & Per Unit Price of Oral Tablet (US$), February’2021
Figure 8-22: Tradjenta - Cost of Daily, Monthly & Annual Treatment (US$)
Figure 8-23: US - Alogliptin Patent Approval & Expiration Year
Figure 8-24: US - Alogliptin FDA Approval & Patent Expiration Year
Figure 8-25: Nesina - Cost of Supply of 30 & Per Unit Price of Oral Tablet (US$), February’2021
Figure 8-26: Nesina -Recommended Initial Dose & Subsequent Reductions (mg)
Figure 9-1: US - Canagliflozin Patent Approval & Expiration Year
Figure 9-2: Invokana - Cost of Supply of 30 & Per Unit Price of Oral Tablet (US$), February’2021
Figure 9-3: Invokana - Cost of Supply of 90 & Per Unit Price of Oral Tablet (US$), February’2021
Figure 9-4: Invokana - Maximum & Minimum Recommended Dose (mg)
Figure 9-5: Global - Invokana Annual Sales (US$ Million), 2017-2019
Figure 9-6: US - Invokana Annual Sales (US$ Million), 2017-2019
Figure 9-7: Invokana - Annual Sales by Region (%), 2019
Figure 9-8: Global - Invokana Quarterly Sales (US$ Million), 2019 & 2020
Figure 9-9: US - Invokana Quarterly Sales (US$ Million), 2019 & 2020
Figure 9-10: Invokana - Annual Sales by Region (%), 2020
Figure 9-11: US - Ertugliflozin FDA Approval & Patent Exclusivity Year
Figure 9-12: US - Ertugliflozin Patent Approval & Expiration Year
Figure 9-13: Steglatro - Cost of Supply of 30 & Per Unit Price of Oral Tablet (US$), February’2021
Figure 9-14: Steglatro - Cost of Supply of 90 & Per Unit Price of Oral Tablet (US$), February’2021
Figure 9-15: Steglatro - Cost of Supply of 500 & Per Unit Price of Oral Tablet (US$), February’2021
Figure 9-16: Steglatro - Maximum & Minimum Recommended Dose (mg)
Figure 9-17: US - Ertugliflozin Patent Approval & Expiration Year
Figure 9-18: Jardiance - Cost of Supply of 30 & Per Unit Price of Oral Tablet (US$), February’2021
Figure 9-19: Jardiance - Cost of Supply of 90 & Per Unit Price of Oral Tablet (US$), February’2021
Figure 9-20: Jardiance - Maximum & Minimum Recommended Dose (mg)
Figure 9-21: Global - Jardiance Annual Sales (US$ Million), 2017-2020
Figure 9-22: US - Linagliptin FDA Approval & Patent Expiration Year
Figure 9-23: US - Dapagliflozin Patent Approval & Expiration Year
Figure 9-24: Farxiga - Cost of Supply of 30 & Per Unit Price of Oral Tablet (US$), February’2021
Figure 9-25: Farxiga - Maximum & Minimum Recommended Dose (mg)
Figure 9-26: Global - Farxiga Annual Sales (US$ Million), 2017-2019
Figure 9-27: US - Farxiga Annual Sales (US$ Million), 2017-2019
Figure 9-28: Farxiga - Annual Sales by Region (%), 2019
Figure 9-29: Global - Farxiga Quarterly Sales (US$ Million), 2020
Figure 9-30: US - Farxiga Quarterly Sales (US$ Million), 2020
Figure 9-31: Farxiga - Annual Sales by Region (%), 2020
Figure 10-1: Repaglinide - Cost of Supply of 100 & Per Unit Price of Oral Tablet of 0.5mg (US$), February’2021
Figure 10-2: Repaglinide - Cost of Supply of 30, 100 & 500 Oral Tablets of 1mg (US$), February’2021
Figure 10-3: Repaglinide - Cost of Supply of 100 & 500 Oral Tablets of 2mg (US$), February’2021
Figure 10-4: Repaglinide - Maximum & Minimum Recommended Dose (mg)
Figure 10-5: Nateglinide - Cost of Supply of 30, 90 & 100 Oral Tablets of 60mg (US$), February’2021
Figure 10-6: Nateglinide - Cost of Supply of 30, 90 & 100 Oral Tablets of 120mg (US$), February’2021
Figure 11-1: US - Miglitol FDA Approval & Generic Availability Year
Figure 11-2: Glyset - Cost of Supply of 100 & Per Unit Price of 25mg Oral Tablet (US$), February’2021
Figure 11-3: Glyset - Cost of Supply of 100 & Per Unit Price of 50mg Oral Tablet (US$), February’2021
Figure 11-4: Glyset - Cost of Supply of 100 & Per Unit Price of 100mg Oral Tablet (US$), February’2021
Figure 11-5: Miglitol - Cost of Supply of 100 & Per Unit Price of 25mg Oral Tablet (US$), February’2021
Figure 11-6: Miglitol - Cost of Supply of 100 & Per Unit Price of 50mg Oral Tablet (US$), February’2021
Figure 11-7: Miglitol - Cost of Supply of 100 & Per Unit Price of 100mg Oral Tablet (US$), February’2021
Figure 11-8: Miglitol - Maximum & Minimum Recommended Dose (mg)
Figure 11-9: Acarbose - Cost of Supply of 90, 100 & 1000 Oral Tablets of 25mg (US$), February’2021
Figure 11-10: Acarbose - Cost of Supply of 90, 100 & 1000 Oral Tablets of 50mg (US$), February’2021
Figure 11-11: Acarbose - Cost of Supply of 90, 100 & 1000 Oral Tablets of 100mg (US$), February’2021
Figure 11-12: Acarbose - Maximum Recommended Dose by Weight (mg)
Figure 12-1: US - Metformin/Sitagliptin FDA Approval by Brand
Figure 12-2: US - Janumet Patent Approval & Expiration Year
Figure 12-3: US - Janumet XR Patent Approval & Expiration Year
Figure 12-4: Janumet - Cost of Supply of 60, 180 & 1000 Oral Tablets (US$), February’2021
Figure 12-5: Janumet XR - Cost of Supply of 60, 180 & 1000 Oral Tablets (US$), February’2021
Figure 12-6: Global - Janumet Annual Sales (US$ Million), 2017-2019
Figure 12-7: US - Janumet Annual Sales (US$ Million), 2017-2019
Figure 12-8: Janumet - Annual Sales by Region (%), 2019
Figure 12-9: Global - Janumet Quarterely Sales (US$ Million), 2020
Figure 12-10: US - Duetact FDA Approval & Generic ApprovalYear
Figure 12-11: US - Duetact Patent Approval & Expiration Year
Figure 12-12: Duetact - Cost of Supply of 30 & Per Unit Price of Oral Tablet (US$), February’2021
Figure 12-13: Glimepiride/Pioglitazone - Cost of Supply of 30 & Per Unit Price of 2mg-30mg Oral Tablet (US$), February’2021
Figure 12-14: Glimepiride/Pioglitazone - Cost of Supply of 30 & Per Unit Price of 4mg-30mg Oral Tablet (US$), February’2021
Figure 12-15: US - Glyburide/Metformin FDA Approval & Generic Availability Year
Figure 12-16: Glucovance - Cost of Supply of 100 & Per Unit Price of Oral Tablet (US$), February’2021
Figure 12-17: Glyburide/Metformin - Cost of Supply of 100 & 500 Oral Tablets of 1.25mg (US$), February’2021
Figure 12-18: Glyburide/Metformin - Cost of Supply of 100 & 500 Oral Tablets of 2.5mg (US$), February’2021
Figure 12-19: Glyburide/Metformin - Cost of Supply of 100 & 500 Oral Tablets of 2.5mg (US$), February’2021
Figure 12-20: Glyburide/Metformin - Maximum & Minimum Recommended Dose (mg)
Figure 12-21: US - Dapagliflozin/Metformin Patent Approval & Expiration Year
Figure 12-22: Xigduo - Cost of Supply of 30 & Per Unit Price of Oral Tablet (US$), February’2021
Figure 12-23: US - Synjardy Patent Approval & Expiration Year
Figure 12-24: US - Synjardy XR Patent Approval & Expiration Year
Figure 12-25: Synjardy - Cost of Supply of 60 & Per Unit Price of Oral Tablet (US$), February’2021
Figure 12-26: Synjardy - Cost of Supply of 180 & Per Unit Price of Oral Tablet (US$), February’2021
Figure 12-27: Glipizide/Metformin - Cost of Supply of 100 & Per Unit Price of 2.5mg-250mg Oral Tablet (US$), February’2021
Figure 12-28: Glipizide/Metformin - Cost of Supply of 100 & Per Unit Price of 2.5mg-500mg Oral Tablet (US$), February’2021
Figure 12-29: Glipizide/Metformin - Cost of Supply of 100 & Per Unit Price of 5mg-500mg Oral Tablet (US$), February’2021
Figure 12-30: US - Linagliptin/Metformin FDA Approval by Brand
Figure 12-31: US - Jantadueto Patent Approval & Expiration Year
Figure 12-32: Jantadeuto - Cost of Supply of 60 & Per Unit Price of Oral Tablet (US$), February’2021
Figure 12-33: Jantadeuto - Cost of Supply of 180 & Per Unit Price of Oral Tablet (US$), February’2021
Figure 12-34: Jantadeuto XR - Cost of Supply of 60 & Per Unit Price of 2.5mg-1000mg Oral Tablet (US$), February’2021
Figure 12-35: Jantadeuto XR - Cost of Supply of 180 & Per Unit Price of 2.5mg-1000mg Oral Tablet (US$), February’2021
Figure 12-36: Jantadeuto XR - Cost of Supply of 30 & Per Unit Price of 2.5mg-1000mg Oral Tablet (US$), February’2021
Figure 12-37: Jantadeuto XR - Cost of Supply of 90 & Per Unit Price of 5mg-1000mg Oral Tablet (US$), February’2021
Figure 12-38: US - Metformin/Pioglitazone FDA Approval & Generic Availability Year
Figure 12-39: US - ActoPlus Met Patent Approval & Expiration Year
Figure 12-40: ActoPlus Met - Cost of Supply of 60 & Per Unit Price of Oral Tablet (US$), February’2021
Figure 12-41: ActoPlus Met - Cost of Supply of 180 & Per Unit Price ofOral Tablet (US$), February’2021
Figure 12-42: Metformin/Pioglitazone - Cost of Supply of 60 & Per Unit Price of 850mg-15mg Oral Tablet (US$), February’2021
Figure 12-43: ActoPlus Met - Cost of Supply of 180 & Per Unit Price of 850mg-15mg Oral Tablet (US$), February’2021
Figure 12-44: Metformin/Pioglitazone - Cost of Supply of 60 & Per Unit Price of 500mg-15mg Oral Tablet (US$), February’2021
Figure 12-45: ActoPlus Met - Cost of Supply of 180 & Per Unit Price of 500mg-15mg Oral Tablet (US$), February’2021
Figure 12-46: US - BMS’s Kombiglyze XR Patent Issue & Expiration Year
Figure 12-47: US - AstraZeneca’s Kombiglyze XR Patent Issue & Expiration Year
Figure 12-48: Kombiglyze XR - Price for 60 Tablets Supply & Price Per Unit Tablet of 1000mg-2.5mg Dose (US$), February’2021
Figure 12-49: Kombiglyze XR - Price for 30 Tablets Supply & Price Per Unit Tablet of 1000mg-2.5mg Dose (US$), February’2021
Figure 12-50: Kazano - FDA Approval & Authorized Generic Approval Year
Figure 12-51: US - Kazano Patent Issue & Expiration Year
Figure 12-52: Kazano - Price for 60 Tablets Supply & Price Per Unit Tablet of Various Dose Regimens (US$), February’2021
Figure 12-53: Kazano Authorized Generic - Price for 60 Tablets Supply & Price Per Unit Tablet of Various Dose Regimens (US$), February’2021
Figure 12-54: Oseni - FDA Approval & Authorized Generic Approval Year
Figure 12-55: US - Oseni Patent Issue & Expiration Year
Figure 12-56: Oseni - Price for 30 Tablets Supply & Price Per Unit Tablet of Various Dose Regimens (US$), February’2021
Figure 12-57: Oseni Authorized Generic - Price for 30 Tablets Supply & Price Per Unit Tablet of Various Dose Regimens (US$), February’2021
Figure 12-58: Invokamet - FDA Approval Year by Dosage Form
Figure 12-59: US - Invokamet Patent Issue & Expiration Year
Figure 12-60: Invokamet - Price for 60 Tablets Supply & Price Per Unit Tablet of Various Dose Regimens (US$), February’2021
Figure 12-61: US - Mitsubishi’s Invokamet XR Patent Issue & Expiration Year
Figure 12-62: US - DepoMed’s Invokamet XR Patent Issue & Expiration Year
Figure 12-63: Invokamet XR - Price for 60 Tablets Supply & Price Per Unit Tablet of Various Dose Regimens (US$), February’2021
Figure 12-64: US - Qtern Patent Issue & Expiration Year
Figure 12-65: Qtern - Price for 30 Tablets Supply & Price Per Unit Tablet of Various Dose Regimens (US$), February’2021
Figure 12-66: Qtern - Minimum & Maximum Daily Dose (mg/day)
Figure 12-67: US - Trijardy XR Patent Issue & Expiration Year
Figure 12-68: Trijarydy XR - Price for 30 Tablets Supply & Price Per Unit Tablet of 10mg-5mg-1000mg & 25mg-5mg-1000mg Dose (US$), February’2021
Figure 12-69: Trijarydy XR - Price for 90 Tablets Supply & Price Per Unit Tablet of 10mg-5mg-1000mg & 25mg-5mg-1000mg Dose (US$), February’2021
Figure 12-70: Trijarydy XR - Price for 60 Tablets Supply & Price Per Unit Tablet of 25mg-2.5mg-1000mg and 5mg-2.5mg-1000mg Dose (US$), February’2021
Figure 12-71: Trijarydy XR - Price for 180 Tablets Supply & Price Per Unit Tablet of 25mg-2.5mg-1000mg and 5mg-2.5mg-1000mg Dose (US$), February’2021
Figure 12-72: US - Cycloset Patent Issue & Expiration Year
Figure 12-73: Glyxambi - Price for 30 Tablets Supply & Price Per Unit Tablet of Various Dose Regimens (US$), February’2021
Figure 12-74: Glyxambi - Price for 90 Tablets Supply & Price Per Unit Tablet of Various Dose Regimens (US$), February’2021
Figure 12-75: Glyxambi - Minimum & Maximum Daily Dose (mg/day)
Figure 12-76: US -Patent Segluromet Issue & Expiration Year
Figure 12-77: Segluromet - Price for 60 Tablets Supply & Price Per Unit Tablet of Various Dose Regimens (US$), February’2021
Figure 12-78: Segluromet - Price for 180 Tablets Supply & Price Per Unit Tablet of Various Dose Regimens (US$), February’2021
Figure 12-79: Segluromet - Price for 500 Tablets Supply & Price Per Unit Tablet of Various Dose Regimens (US$), February’2021
Figure 12-80: US - Merck’s Steglujan Patent Issue & Expiration Year
Figure 12-81: US - Pfizer’s Steglujan Patent Issue & Expiration Year
Figure 12-82: Steglujan - Price for 30 Tablets Supply & Price Per Unit Tablet of Both Dose Regimens (US$), February’2021
Figure 12-83: Steglujan - Price for 90 Tablets Supply & Price Per Unit Tablet of Both Dose Regimens (US$), February’2021
Figure 12-84: Steglujan - Minimum & Maximum Daily Dose (mg/day)
Figure 13-1: US - Cycloset Patent Issue & Expiration Year
Figure 13-2: Cycloset - Price for 200 Tablets Supply & Price Per Unit Tablet (US$), February’2021
Figure 13-3: Cycloset - Minimum & Maximum Daily Dose (mg/day)
Figure 13-4: Cycloset - Minimum & Maximum Daily Treatment Cost (US$), February’2021
Figure 13-5: Welchol - FDA Approval Year by Dosage Form
Figure 13-6: US - Welchol Patent Issue & Expiration Year
Figure 13-7: Welchol - Price for 30 Powders Supply & Price Per Unit of Oral Powder for Reconstitution (US$), February’2021
Figure 13-8: Welchol - Price for 180 Tablets Supply & Price Per Unit Tablet (US$), February’2021
Figure 13-9: Generic Colesevelam - Price for Various Supplies of Oral Tablet (US$), February’2021
Figure 13-10: Colesvelem - Cost of Daily Treatment Using Branded & Generic Tablet (US$), February’2021
Figure 13-11: Symlin Pen 60 - Price for 3ml Supply & Price Per ml of Subcutaneous Solution (US$), February’2021
Figure 13-12: Symlin Pen 120 - Price for 5.4ml Supply & Price Per ml of Subcutaneous Solution (US$), February’2021
Figure 13-13: Symlin - Recommended Dose by Diabetes Type (mcg/Meal), February’2021

• AstraZeneca
• Boehringer Ingelheim
• Daiichi Sankyo
• Eli Lilly
• GSK
• Janssen Pharma
• Merck
• Novartis
• Novo Nordisk
• Pfizer
• Sanofi
• Takeda